Panic disorder patients have reduced cyclic AMP in platelets.

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• Intracellular mechanisms in panic disorder (PD) pathophysiology remain largely unknown.
• Cyclic AMP system abnormalities are implicated in various psychiatric disorders, but not previously studied in PD.
• Platelet function offers a model for investigating systemic biochemical alterations in PD.

Purpose of the Study:

• To investigate intracellular cyclic AMP, cyclic GMP, and nitric oxide synthase (NOS) activity in PD patients.
• To compare these levels in PD patients at baseline, after clomipramine treatment, and in healthy controls.
• To explore the role of the cyclic AMP system in PD and its modulation by clomipramine.

Main Methods:

• Enzyme immunoassay for platelet cyclic AMP determination.
• Radioimmunoassay for platelet cyclic GMP measurement.
• Nitric oxide synthase (NOS) activity assay using (3)H-arginine conversion in 17 PD patients and 22 healthy volunteers.

Main Results:

• PD patients at baseline showed significantly lower platelet cyclic AMP levels compared to both post-treatment and healthy volunteers (P<0.005).
• Following successful clomipramine treatment and remission of panic attacks, cyclic AMP levels in PD patients normalized and were not significantly different from healthy controls.
• No significant differences were observed in cyclic GMP levels or NOS activity across the study groups.

Conclusions:

• Untreated panic disorder is associated with reduced platelet cyclic AMP levels.
• Clomipramine treatment appears to correct the cyclic AMP deficit in PD patients.
• The cyclic AMP system represents a potential therapeutic target for managing panic disorder.